Sung Lee | Senior Vice President, Investor Relations |
Daniel O'Day | Chairman & Chief Executive Officer |
Johanna Mercier | Chief Commercial Officer |
Robin Washington | Executive Vice President & Chief Financial Officer |
Diana Brainard | Senior Vice President, HIV and Emerging Viral Infections |
Matthew Harrison | Morgan Stanley |
Brian Abrahams | RBC Capital Markets |
Michael Yee | Jefferies |
Geoff Porges | Leerink |
Alethia Young | Cantor Fitzgerald |
Carter Gould | UBS |
Umer Raffat | Evercore |
Mohit Bansal | Citi |
Cory Kasimov | JPMorgan |
Phil Nadeau | Cowen and Company |
Salim Syed | Mizuho |
Hartaj Singh | Oppenheimer |
Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences' Second Quarter 2019 Earnings Conference Call. My name is Liz and I will be your conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Sung Lee, Senior Vice President, Investor Relations.